Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of Concomitant Vaccination With IC51 and HARVIX® 1440 in Healthy Subjects. A Single-blind Randomized, Controlled Phase 3 Study

NCT00596271 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT00596271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00596271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of Concomitant Vaccination With IC51 and HARVIX® 1440 in Healthy Subjects. A Single-blind Randomized, Controlled Phase 3 Study
Lead sponsor
Valneva Austria GmbH
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2005
Completion date
August 31, 2008
Enrollment
192 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

japanese encephalitis